
















48Combined Effects of Interleukin-7 and Stem Cell Factor
Administration on Lymphopoiesis after Murine Bone
Marrow Transplantation
Brile Chung,1 Dullei Min,1 Lukas W. Joo,2 Mark R. Krampf,1 Jing Huang,1 Yujun Yang,1
Sumana Shashidhar,1 Janice Brown,1 Eric P. Dudl,2 Kenneth I. Weinberg1The decreased ability of the thymus to generate T cells after bonemarrow transplantation (BMT) is a clinically
significant problem. Interleukin (IL)-7 and stem cell factor (SCF) induce proliferation, differentiation, and
survival of thymocytes. Although previous studies have shown that administration of recombinant human
IL-7 (rhIL-7) after murine and human BMT improves thymopoiesis and immune function, whether adminis-
tration of SCF exerts similar effects is unclear. To evaluate independent or combinatorial effects of IL-7 and
SCF in post-BMT thymopoiesis, bone marrow (BM)-derived mesenchymal stem cells transduced ex vivo with
the rhIL-7 or murine SCF (mSCF) genes were cotransplanted with T cell–depleted BM cells into lethally
irradiated mice. Although rhIL-7 and mSCF each improved immune reconstitution, the combination treat-
ment had a significantly greater effect than either cytokine alone. Moreover, the combination treatment
significantly increased donor-derived common lymphoid progenitors (CLPs) in BM, suggesting that trans-
planted CLPs expand more rapidly in response to IL-7 and SCF and may promote immune reconstitution.
Our findings demonstrate that IL-7 and SCF might be therapeutically useful for enhancing de novo T cell
development. Furthermore, combination therapy may allow the administration of lower doses of IL-7,
thereby decreasing the likelihood of IL-7–mediated expansion of mature T cells.
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The loss of postnatal thymic function due to che-
motherapy, radiation, aging, human immunodefi-
ciency virus (HIV) infection, and graft-versus-host
disease (GVHD) is a major problem contributing to
the increased risk of infection in certain clinical
settings, notably cancer chemotherapy, hematopoietic
stem cell transplantation (HSCT), HIV infection, and
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6/j.bbmt.2010.07.027appears to result from injury or loss of the thymic
micronenvironment, particularly of thymic epithelial
cells (TECs) [5,8,11]. The ability of adolescents and
adults to generate thymic-derived new T lymphocytes
is significantly diminished after receiving preparative
chemotherapy or radiotherapy for HSCT [12,13].
Further complicating allogeneic HSCT is the
targeting and killing of TECs by alloreactive T cells
[14]. Thymic insufficiency limits or delays the capacity
of HSCT recipients to reconstitute their T cell com-
partment, contributing to an increased susceptibility
to opportunistic infections and viral-associated malig-
nancies [15].
Interleukin (IL)-7 and stemcell factor (SCF; aKit li-
gand) are the major lymphopoietic cytokines produced
in the thymus and bone marrow compartment [16-18].
IL-7 induces proliferation, differentiation, and survival
of immature T lymphocytes throughout development.
During normal T cell development in the thymus,
IL-7 andSCF, producedbyTECs, bind to their cognate
IL-7R and Kit receptors expressed on the surface of
immature T lymphoid progenitor cells. IL-7 stimulates
the differentiation of immature CD32CD42CD82
(triple-negative [TN]) thymocytes to later stages,
ultimately resulting in the development of mature
Biol Blood Marrow Transplant 17:48-60, 2011 49Combined IL-7 and SCF Treatment in Murine BMTCD41CD82 orCD4-CD81Tcells.The importance of
IL-7 for thymopoiesis is demonstrated bymicewith tar-
geted mutations of the IL-7, IL-7 receptor a, or com-
mon g chain (gc) gene; dogs with X severe combined
immunodeficiency (SCID) (gc mutations); and humans
with IL-7R–deficient SCID or X-SCID—all of which
have defective thymopoiesis and impaired ability to pro-
duce T lymphocytes [18-21]. We and others have
previously shown that administration of recombinant
human IL-7 (rhIL-7) corrects the thymopoietic defects
observed after histocompatible BMT, suggesting that
post-BMTIL-7administrationmightbeapotential ther-
apy for posttransplantation immunodeficiency [22-25].
The role of SCF in T cell development has been
described in mice with mutations of SCF (SL/SL) or
its receptor, Kit (receptor tyrosine kinase), which have
significantly lower numbers of thymocytes compared
with their wild-type counterparts [16,26]. Analyses of
Kit- or SCF-deficient mice by bromodeoxyuridine
administration in vivo have shown that approximately
50%of theproliferationofTNthymocytes is dependent
on the Kit-signaling pathway. Furthermore, the
addition of SCF has been reported to increase TN
thymocytes in vitro, and the administration of anti-Kit
antibody blocks the ability of TN thymocytes to
develop into mature T cells, demonstrating the
importance of SCF in the early stage of T lymphocyte
development [27,28]. Interestingly, the Kit pathway
interacts directly with other cytokine receptors of
hematopoietic progenitors, notably IL-3R, erythropoi-
etin receptor, and IL-7R [29-32]. In addition, mice
that are doubly mutant for Kit and for gc, IL-7, or
IL-7Ra exhibit complete failure of T cell development,
profoundly more severe than that observed in either pa-
rental strain [26,33]. Thus, the IL-7 and SCF signaling
pathways are essential, redundant, and partially syner-
gistic during T cell generation.
Here we hypothesize that BM-derivedmesenchymal
stem cells (MSCs) transduced with a retroviral vector
containing either IL-7 or SCF cDNA would be a safe
and efficient delivery vehicle for the administration of ei-
ther cytokine alone or both cytokines together. The
transduced MSCs would produce IL-7 or SCF continu-
ously,which ismorephysiological than thehigh intermit-
tent doses administered in other systemic cytokine
treatment studies, including our previous study of IL-7
injections [22,34,35]. In the present study, we
demonstrate that cotransplantation of BM and BM-
derived MSCs stably transduced with either the IL-7 or
SCF genes resulted in enhanced thymopoiesis and im-
mune reconstitution. Moreover, combined IL-7 and
SCF therapy had a greater effect on the expansion of
common lymphoid progenitors (CLPs), enhancement
of donor-derived thymopoiesis, and peripheral T cell re-
covery compared with either cytokine treatment alone,
suggesting that combined IL-7 andSCFtherapy canpro-
mote thymopoiesis andT cell reconstitution after BMT.MATERIALS AND METHODS
Mice
Eight- to 10-week-old female recipient mice
(C57BL/6J [CD45.21]) andmale donormice (congenic
B6.SJL [CD45.11]) were purchased from Jackson
Laboratory (Bar Harbor, ME). The mice were kept in
laminar flow cages with autoclaved food and acidified
water. The protocol for maintaining the animals before
and after BMT was approved by Stanford University’s
Animal Care Committee.Generation and Transduction of BM-Derived
MSCs
Three retroviral vectors—MND-SCF-IRES-
EGFP, MND-IL-7-IRES-EGFP, and MND-
EGFP—were used to transduce MSCs. These
retroviral vectors were generated at the Vector Core
Laboratory under the direction of Dr. Donald Kohn
at Children’s Hospital Los Angeles, and contain either
the rhIL-7 or murine SCF (mSCF) cDNA under
transcriptional control of the Moloney murine leuke-
mia virus (M-MuLV) long terminal repeat (LTR).
Transcription of enhanced green fluorescent protein
(EGFP) is controlled by an internal ribosomal entry
site (IRES). Supernatants containing each vector
were prepared by infection of the PA317 amphotropic
packaging cell line with titers of 1  106. BM-derived
MSC cultures were generated from 8- to 10-week-old
C57BL/6J (CD45.21) mice. After sacrifice, the femurs
were dissected and the medullary cavity was flushed
and then crushed. Both BM fragments and the BM
cavity were cultured on the tissue culture dishes in
DOM medium to produce an adherent cell layer. At
approximately 80% confluence, CD451 cells were
removed using rat anti-CD45 monoclonal antibody
(BD Pharmingen, San Diego, CA) and immunomag-
netic beads (Dynal, Great Neck, NY). After generation
of MSCs, the cells were transduced by the addition
of MND-EGFP only, MND-IL-7 IRES EGFP, or
MND-SCF IRES EGFP retroviral supernatants in
the presence of 4 mg/mL of protamine sulfate. A total
of 4 exposures to retroviral supernatant over 2 days
was used to transduce the cells. After transduction,
isolation of EGFP1 cells was performed using
fluorescence-activated cell sorting (FACS). MSC
production of IL-7 and SCF was measured after
plating 1  106 transduced MSCs in 1 mL of medium
in individual wells of 6-well plates. After 24 hours, the
medium was collected and serial dilutions were tested
using an enzyme-linked immunosorbent assay
(ELISA) kit for detection of rhIL-7 and SCF (R&D
Systems, Minneapolis, MN). The mean of duplicate
samples was expressed as pg of IL-7 or SCF produced
per 106 cells in 24 hours.
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Female recipient C57BL/6J (CD45.2) mice were
given two separate doses of radiation (700 cGy on
day 21 and 600 cGy on day 0). The BM cells from
B6.SJL (CD45.1) donor mice were obtained by perfu-
sion of the femur. The donor BM cells were depleted
for mature T lymphocytes by immmunomagnetic
depletion, using rat anti-mouse Thy 1.2, CD4, and
CD8 monoclonal antibodies (BD Pharmingen) and
sheep anti-rat antibodies conjugated to beads (Dynal).
Each recipient mouse received\1000 T (Thy 1.21)
cells, as determined by FACS of the infused marrow
(\0.1% contamination). After irradiation of recipient
mice, 1  106 T cell–depleted (TCD) BM and differ-
ent dosages of transduced MSCs were cotransplanted
into recipients via tail vein injection. In each experi-
ment, a group of mice received irradiation but no
transplanted TCD BM cells, to confirm delivery of a
lethal dose of radiation.Immunophenotyping
BMTrecipientswere sacrificed byCO2 narcosis, af-
ter which the thymus, spleen, and BM cells were
removed. Single-cell suspensions of each organ were
prepared, and the total cell numbers were determined.
Then 1  105 cells were stained with conjugated anti-
bodies directed against Thy-1.2, CD3, CD4, CD8,
CD45.1, CD45.2, B220, CD11b, GR1, CD25, CD44,
Ter119, or isotype control monoclonal antibodies
(BDPharmingen). To identify hematopoietic stem cells
(HSCs) or CLPs, BM cells also were stained with con-
jugated antibodies against Kit, Sca-1, and IL-7Ra. After
staining, cells were washed and analyzed on a FACSCa-
libur analyzer (BD Biosciences, San Jose, CA).ELISA for Detection of rhIL-7 and mSCF
The rhIL-7 andmSCF concentrations in the serum
samples were measured using a commercially available
high-sensitivity ELISA kit (R&D Systems) in accor-
dance with the manufacturer’s instructions. A standard
curve was prepared for each plate, plotting optical den-
sity versus various concentrations of rhIL-7 andmSCF.
All standards and samples were tested in duplicate.Histology
Spleen, liver, and thymic tissues were fixed in 4%
paraformaldehyde for 30 minutes and then embedded
in 1.5% gelatin containing 0.12 M phosphate buffer
(Sigma-Aldrich, St Louis, MO). The gelatin-embedded
tissue samples were dried for 15 minutes and then care-
fully sectionedusing aLeicaVT1000S vibrotome (Leica
Microsystems, Bannockburn, IL). Then 30-mm sections
of each tissue sample were examined for EGFP expres-
sionusing aLeicaTCSSP1 confocalmicroscope.Tissue
sections from the recipients of nontransduced MSCswere used to establish the lowest threshold of EGFP
intensity.
Sheep Red Blood Cell Immunization
Normal and recipient mice were immunized with
sheep red blood cells (SRBCs; Colorado Serum,Denver,
CO) via i.p. injection at day 30 post-BMT. After 2
weeks, peripheral blood was drawn for assessment of pri-
mary antibody responses against SRBCs, and the mice
wereboostedwithSRBCs for secondary responses,which
were measured 1 week later. The agglutination antibody
titers in the serumwere determined by serial dilution and
incubation with SRBCs in 96-well V-bottomed micro-
plates (Corning, Corning, NY).
Statistical Analyses
Different immunophenotypic populations of cells
after transplantation were analyzed using the two-
tailed t test with unequal distributions. A P value #.05
was considered statistically significant.RESULTS
Generation and Characterization of IL-7–
and SCF-Transduced MSCs
We took an IL-7 and SCF gene therapy approach
using retrovirally mediated transduction of BM-
derived MSCs. We hypothesized that continuous
production of either IL-7 or SCF by MSCs would be
more physiological than boluses of cytokine injections,
and that the transduced MSCs could be transplanted
into the lymphoid organs. We chose BM-derived
MSCs as an efficient delivery vehicle for the administra-
tion of cytokine, because MSCs are derived from the
hematopoietic niche and readily expand in vitro. In
addition, BM MSCs have been reported to support
hematopoiesis after cotransplantation of BM MSCs
with HSCs in several animal experiments [36,37]. To
generate BM-derived MSCs, BM stromal cells from
8- to 10-week-old C57BL/6J mice were collected and
cultured in vitro based on their ability to bind to tissue
culture plates, followed by depletion of CD451 cells to
exclude all hematopoietic lineage–derived cells. After
enrichment, the cells expressed the BM-derived MSC
markers CD90, CD105, Sca-1, and CD44 (Figure 1A).
In addition, the BM-derived MSCs were able to
differentiate into different mesenchymal lineages (adi-
pogenesis, osteogenesis, and myogenesis), as described
previously (data not shown) [38].
To transduce MSCs, we generated the retroviral
vectors expressing EGFP only (MND-EGFP), rhIL-7
cDNA (MND-hIL-7-IRES-EGFP), or mSCF (se-
creted form) cDNA (MND-mSCF-IRES-EGFP)
(Figure 1B). After retroviral supernatants were added
to the culturedMSCs, the transducedMSCswere sorted
Figure 1. Phenotypic characterization of BM-derived MSCs and schematic diagrams of of MND-IL-7-IRES-EGFP, MND-SCF-IRES-EGFP, and MND-
EGFP vectors. In an IL-7 and SCF gene therapy approach using retrovirally mediated transduction, murine BM–derived MSCs were generated and
used as a delivery vehicle for the administration of cytokine. (A) Characterization of cell surface markers expressed on BM-derived MSCs. The majority
of BM-derived MSCs were positive for CD105, CD90, CD44, and Sca-1 and negative for CD45. (B) The MND LTR is based on the M-MuLV LTR, and the
vectors were constructed so that the LTR drives expression of the EGFP reporter gene, rhIL-7 cDNA, or mSCF cDNA. Both IL-7 and SCF vectors
contain an IRES in which the EGFP marker gene is expressed downstream of the IRES. The imunofluorescence image of MSC tranduced with the
MND vector is shown on the right.
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production of rhIL-7 and mSCF. In several experi-
ments, small amounts of both IL-7 (5 pg/L  106
cells/24 hours) and SCF (20 pg/L 106 cells/24 hours)
wereproducedby theMSCs transducedwith theMND-
EGFP vector. In contrast, the MSCs transduced with
MND-hIL-7-IRES-EGFP or MND-mSCF-IRES-
EGFP vector produced large amounts of IL-7 (1600
pg/L  106 cells/24 hours) and SCF (1200 pg/L  106
cells/24 hours) (data not shown).
Engraftment of Transduced MSCs
and Circulating Levels of rhIL-7 and mSCF
in BMT Recipients
Because the IL-7 and SCFMSCs were injected i.v.,
MSC engraftment in multiple sites was expected. Atthe time of sacrifice, organs were separated, sectioned,
and visualized under fluorescent microscopy. The level
of fluorescence was sufficient to allow tracking of
transduced cells after transplantation, and we detected
EGFP-positiveMSCs in lymphohematopoietic organs
(eg, marrow, spleen, liver) (Figure 2A). We also mea-
sured the circulating levels of both rhIL-7 and mSCF
in peripheral blood of recipients of transduced MSCs
at day 30 to evaluate whether engrafted MSCs were
capable of secreting the cytokines. The serum samples
from recipients of IL-7 or/and SCF MSCs displayed
increased levels of circulating rhIL-7 or/and mSCF
compared with EGFP MSC control animals, and
mice receiving 0.3  106 transduced MSCs had
significantly higher rhIL-7 levels than those receiving
0.1 106 MSCs. The SCF assays were complicated by
Figure 2. In vivo detection of transduced MSCs at day 30 post-BMT and serum levels of rhIL-7 and mSCF. After cotransplantation of TCD BM and
transduced MSCs, EGFP-expressing cells were detected in the tissue sections of BM, spleen, and liver by fluorescence microscopy at day 30. (Original
magnification, 200.) (A) After cotransplantation of TCD BM and retrovirally transduced MSCs, serum levels of rhIL-7 and mSCF were measured in
recipient mice at day 30. (B and C) Increased serum levels of rhIL-7 (B) and mSCF (C) were in mice that underwent transplantation with rIL-7 and/
or mSCF MSCs. All values are mean 6 standard deviation; an asterisk indicates significant differences. Each vertical bold line branching off from the
top of the horizontal lines represent statistically significant P values when the 0.3  106 IL-7 1 0.3  106 SCF, 0.1  106 IL-7 1 0.3  106 SCF, and
0.3  106 IL-7 1 0.1  106 SCF groups were individually compared with all other groups of animals. P values for serum rhIL-7 levels: *P #.0005;
**P#.01; ***P#.006. P values for serummSCF levels: *P#.02; **P#.005; ***P#.002). Each value represents themean of two independent experiments
with a total of 3-5 animals per group in each experiment. Consistent results were obtained in repeated experiments throughout.
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SCF does not efficiently transduce signals through
the murine Kit receptor. As a result, the assay detected
both MSC-derived SCF and endogenously generated
SCF. Plasma levels of mSCF were related to the dose
of transplanted SCF MSCs infused, but with greater
intergroup variability (Figure 2B and C).Cotransplantation of IL-7 and SCF MSCs
Increased Donor Thymocytes
At day 30 post-BMT, the amount of donor-derived
thymocytes was measured in the mice that received
transduced MSCs (Figure 3A). Based on previous pub-
lished results by our group and others [5,8,9,22,23],
full donor-derived thymocyte engraftmentwas observed
after experimentalmurineTCDBMTatdays28 and30.
No increment in thymocyte numbers was found inmice
receiving EGFPMSCs comparedwith those not receiv-
ing MSCs. In contrast, the number of donor-derived
thymocytes was greater in the mice that received IL-7and/or SCF MSCs. An incremental increase in thymic
cellularity was related to the number of transduced
IL-7 or SCF MSCs given. In general, transplantation
of IL-7 MSCs resulted in higher donor thymocyte
recovery compared with transplantation of SCF MSCs
alone. Moreover, the combined effect of IL-7 and SCF
resulted in significantly greater number of donor-
derived thymocytes compared with the effect of either
cytokine alone.
Based on our finding that cotransplantation of IL-7
and SCF resulted in greater enhancement of donor-
derived thymopoiesis, we next analyzed the effect of
these cytokines on subpopulations of donor thymo-
cytes. The donor-derived thymocytes were divided
into 4 sequential developmental stages: immature
Thy11CD42CD82 double-negative (DN), interme-
diate Thy11CD41CD81 double-positive (DP), ma-
ture Thy11CD41CD8- single-positive CD4 (SP
CD4), and Thy11 CD4-CD81 single-positive CD8
(SPCD8) (Supplementary Figure 1).We found no sig-
nificant effects of either IL-7 or SCF along on the
Figure 3. Effects of SCF and IL-7 BM-derived MSCs on the numbers of donor-derived thymocytes and thymic subpopulations at day 30 post-BMT. The
number of donor-derived thymocytes (CD45.11Thy11) from each group of transplanted recipient micewas analyzed at day 30 post-BMT. Shown are (A)
numbers of overall donor thymocytes (*P #.0002; **P #.03]), (B) donor DN (Thy11CD42CD82) thymocytes (*P #.05; **P #.03), (C) donor DP
(Thy11CD41CD81) thymocytes (*P #.008; **P #.004), (D) donor SP CD4 (Thy11CD41CD82) thymocytes (*P #.05; **P #.001), and (E) donor
SP CD8 (Thy11CD42CD81) thymocytes (*P#.05; **P#.001). An asterisk indicates significant differences between each group of animals. Each figure
represents the mean of 3 independent experiments, each with a total of 3-5 animals per group. Consistent results were obtained in repeated experi-
ments throughout. Each vertical bold line branching off from the top of the horizontal lines represent statistically significant P values when the 0.3 106
IL-71 0.3  106 SCF, 0.1  106 IL-71 0.3  106 SCF, and 0.3  106 IL-71 0.1  106 SCF groups were individually compared with all other groups of
animals.
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Figure 4. Effects of SCF and IL-7 BM-derived MSCs on the number of donor-derived DN subpopulations at day 30 post-BMT. To analyze and count the
number of donor-derived DN subpopulations, CD45.11CD42CD82 donor thymocytes were gated and analyzed for the expression of CD44 and
CD25. (A) FACS analysis of donor-derived DN cells expressing CD441CD252 (DN1), CD441CD251 (DN2), CD44-CD251 (DN3), and CD442CD252
(DN4). (B-D) Graphs showing the numbers of (B) donor-derived DN1 (*P#.004; **P#.035), (C) DN2 (*P#.05; **P#.05), (D)DN3 (*P#.05; **P#.048),
and (E) DN4 (*P #.025; **P #.036) subpopulations. An asterisk indicates significant differences between each group of animals.
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(data not shown); however, mice treated with both cy-
tokines displayed significantly higher numbers of all 4
subpopulations, with the highest increase in the DN
population (Figure 3B-E).We investigated which sub-
set of donor-derived DN cell populations was most af-
fected by IL-7 and SCF. Based on CD44 and CD25
expression of DN cells, 4 sequential developmental
stages (CD42CD82CD441CD252 [DN1], CD42
CD82CD441CD251 [DN2], CD42CD82CD442
CD251 [DN3], andCD42CD82CD442CD252 [DN4])
were analyzed (Figure 4A). Overall, IL-7 and SCF
resulted in increased levels of all 4 subpopulations for
donor DN cells, with the donor DN3 population
most affected by the combination of IL-7 and SCF
(Figure 4B-E). The combined effects of IL-7 and
SCF acted in a dose-dependent manner, resulting in
an increased number of thymocytes in our current ob-
servation, similar to previous studies reporting that
a combination of IL-7 and SCF enhanced the prolifer-
ation and survival ofmurineCD32CD42CD82 thymo-
cytes, human CD341CD71 thymocytes, human cord
bloodT cells, and a human immatureT cell line in vitro
[39-42]. Thus, our data suggest that proliferation and
expansion were affected by the combined treatment
with IL-7 and SCF, but differentiation was not.Increased Numbers of BM-Derived CLPs
in Recipients of SCF and IL-7 MSCs
Having observed significant differences in the num-
ber of donor-derived thymocytes among recipients of
high and low numbers of IL-7 and/or SCF MSCs, we
further investigated the effects of IL-7 and SCF in an
earlier stage of lymphoid differentiation by examining
the number of donor CLPs in BMT recipients. Murine
CLPs are progenitors for T, B, and NK lymphocytes
and express both IL-7Ra and Kit [43-45]. Recent data
from Krueger et al. [46] suggest that CLPs also play
a crucial role in donor-derived thymic reconstitution
after experimental BMT. Because CLPs coexpress
IL-7R and c-Kit, we were interested in examining
whether the combining effects of IL-7 and SCF increase
the number of donor-derived CLPs in transducedMSC
recipients. Figure 5A shows phenotypic analyses of
murine CLPs in bone marrow in which CLPs are char-
acterized as lineage marker negative (Lin2), Sca-1low,
Thy1.22, Kitlow, and IL-7R1 [47]. At day 30 posttrans-
plantation, the number of CLPs in the BM was signifi-
cantly higher in IL-7 and SCF MSC recipients than in
recipients of MSCs producing either cytokine alone
(Figure 5B). Similar to earlier thymus and spleen data,
the increased number of donor CLPs was related to
the dose of IL-7 and SCF MSCs. The combination of
IL-7 and SCF MSCs demonstrated potentiation of
the individual effects; the addition of IL-7 to suboptimal
SCF doses and vice versa resulted in increased numbersof CLPs. The combination of higher doses (0.3  106
MSCs of each) resulted in significantly greater numbers
of CLPs. Thus, combined IL-7 and SCF therapy ex-
panded the population of BM-derivedCLPs to a greater
extent than did either cytokine alone.
Because HSCs residing in the BM compartment
give rise to CLPs, we also analyzed the number of
donor-derived HSCs (Lin2, Sca-11, Thy1low, Kitl1,
and IL-7R2) in the BM from mice that underwent
HSCT to determine whether the enhanced immune
reconstitution in these animals is related to an overall
increase in donor HSCs [47]. Our analysis showed
that the combined effects of IL-7 and SCF did not
significantly increase the numbers of donor-derived
HSCs in recipients of both IL-7 and SCF MSCs com-
pared with those mice that underwent transplantation
with large amounts of either SCFMSCs (0.3 106) or
IL-7 MSCs (0.3  106). Furthermore, there was no
significant difference in the numbers of donor HSCs
between the recipients of IL-7 (0.1  106)/SCF
(0.3  106) and other mice that underwent HSCT de-
spite the greater donor immune reconstitution seen in
the former group (Supplementary Figure 2). Thus, our
data suggest that the combined effects of IL-7 and SCF
have a significant impact on donor CLP numbers.Increased Peripheral (Splenic) Lymphocytes
in the IL-7 and SCF MSC Group
Similar to donor thymocyte recovery, the number
of donor-derived cells present in the spleens of mice
that underwent HSCT differed significantly between
treatment groups at day 30 after cotransplantation of
transduced MSCs and TCD BM cells (Figure 6A).
The cell recovery from the spleens of animals receiving
IL-7 or SCF alone again showed an association
between the number of donor-derived CD4 T cells,
CD8 T cells, and B cells and the number of cotrans-
planted IL-7 or/and SCF MSCs (Figure 6B and C).
Transplantation of IL-7MSCs resulted in more donor
T cell recovery than that of SCF MSCs, although the
difference was not statistically significant. Again, there
was evidence of potentiated effects of each cytokine by
the other cytokine; mice receiving both IL-7 and SCF
had greater numbers of donor-derived T and B lym-
phocytes than those receiving individual suboptimal
doses, and the maximal effects were observed from
higher doses of cotransplanted IL-7 and SCF MSCs.
The number of donor splenic T cells recovered from
the animals after cotransplantation of 0.1  106 IL-7
MSCs and 0.3 106 SCFMSCs was similar to that re-
covered from animals that received 0.3  106 IL-7
MSCs alone, demonstrating that the reduced prolifer-
ative signals produced by a low dose of IL-7MSCs can
be compensated for by cotransplantation of SCF
MSCs.
Figure 5. Increased numbers of CLPs are seen in mice that underwent cotransplantation with IL-7 and SCF MSCs. To analyze and count the number of
donor-derived CLPs, the BM cells obtained from the femurs of recipient animals were stained with a cocktail of monoclonal antibodies (anti-CD117,
2CD127, –Sca-1, and 2CD45.1) and antilineage cell surface markers (CD3, CD4, CD5, CD8, CD11b, Gr-1, B220, Thy1.2, and Ter119) at day 30
post-BMT. The donor-positive (CD45.11) samples were analyzed for Lin2 IL-7Ra1 Kitlow Sca-1low CLP cells by FACS. (A) FACS analysis of donor-
derived CLPs in the BM of recipient animals. (B) Donor-derived CLPs from each group of mice that underwent cotransplantation with TCD BM and
transduced MSCs. An asterisk indicates significant differences between groups of animals (*P #.006; **P #.003; ***P #.05). The figure represents
the mean of 2 or 3 independent experiments each with a total of 3-5 animals per group. Consistent results were obtained in repeated experiments
throughout. The vertical bold lines branching off from the top of the horizontal lines represent statistically significant P values when the 0.3  106
IL-71 0.3 106 SCF, 0.1 106 IL-71 0.3 106 SCF, and 0.3 106 IL-71 0.1 106 SCF groupswere individually comparedwith all other groups of animals.
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Improved Development of T Cell–Dependent
Antibody Responsiveness after BMT
Because cotransplantation of IL-7 MSC and SCF
MSCs resulted in improvement of donor-derived
thymopoiesis at day 30, we examined functional T
cell–dependent immunity by measuring the antibody
response to SRBCs. The mice were immunized with
SRBCs onday 30 posttransplantation,with a secondary
boost given 2 weeks after primary immunization (day
44). After immunization, we measured primary and
secondary antibody responses directed against SRBCs.
As expected, the recipients of EGFP MSCs displayed
the lowest antibody titer against SRBCs. SCF MSCs
alone had no effect on anti-SRBC titers, whereas
both low and higher doses of IL-7 improved titers,
consistent with previous results [22]. Combinations
of SCF and IL-7 generally yielded greater antibody
titers, with the greatest responses seen in the mice
that received maximal doses of SCF and IL-7 MSCs
(Figure 7). Thus, our data suggest that IL-7 and SCF
MSCs together promote the generation of functional
antigen-specific responsive donor lymphocytes.DISCUSSION
The present study demonstrates that transplanta-
tion of BM-derived MSCs transduced with either the
IL-7 or SCF genes can effectively enhance donor-
derived immune reconstitution after TCD BMT. The
observed effects include increased thymic and splenic
cellularity, increased donor peripheral T andB lympho-
cyte levels, and increased numbers of donor CLPs.
The importance of IL-7 and SCF in thymopoiesis
has been well documented. For example, mice with
mutations of IL-7, gc, SCF, and Kit have decreased
numbers of thymocytes and mature T cells, and
administration of IL-7 or SCF after BMT has been
shown to increase the number of HSC and promote
lymphocyte development in experimental murine
models [16,22,36,48]. However, unlike in IL-72/2 and
IL-7R2/2 mice, the smaller reduction of thymocyte
numbers in SCF/Kit mutant mice suggests that the
Kit pathway appears to interact with multiple other
cytokine receptors in hematopoietic progenitors,
including IL-7R in lymphoid progenitors [30,32].
Mice that are doubly mutated for IL-7 and Kit or for
IL-7R and Kit exhibit a complete loss of thymopoietic
Figure 6. Cotransplantation of IL-7 and SCF MSCs results in increased numbers of donor Tand B cells in the spleen at day 30 post-BMT. We analyzed
the numbers of donor-derived splenic CD41 T cells, CD81 T cells, and B2201 B cells in each group of animals that underwent cotransplantation with
TCD BM and retrovirally transducedMSCs. Shown are numbers of (A) donor Thy11CD41 T lymphocytes (*P#.05; **P#.02), (B) donor Thy11CD81
T lymphocytes (*P#.007; **P#.03), and (C) donor B2201 B cells (*P#.0007; **P#.04) at day 30 in spleen. An asterisk indicates significant differences
between groups of mice. Each value represents the mean of 3 independent experiments each with a total of 3-5 animals per group. Consistent results
were obtained in repeated experiments throughout. The vertical bold lines branching off from the top of the horizontal lines represent statistically sig-
nificant P values when the 0.3 106 IL-71 0.3 106 SCF, 0.1 106 IL-71 0.3 106 SCF, and 0.3 106 IL-71 0.1 106 SCF groups were individually
compared with all other groups of animals.
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have a synergistic affect on the survival, maintenance,
and proliferation of thymocytes [33].
The greater effects of IL-7 and SCF together on
the development of CLPs and lymphoid progenitors
compared with either cytokine alone suggest that
IL-7 and SCF are complementary signals for the
proliferation, survival, and differentiation of these
cells. The partially redundant effects of IL-7 and
SCF on the proliferation of murine thymocytes and
human immature T cell lines in vitro have been
reported previously. The increase in the number of
DN thymocytes was approximately 10-fold greater in
murine fetal thymic lobes cultured in the presence of
IL-7 and SCF than in thymic lobes cultured with
IL-7 or SCF alone [39]. Similar to murine studies,
the proliferative response of the immature human Tcell line expressing CD34 and CD7 was significantly
greater in the presence of both IL-7 and SCF than in
the presence of either cytokine alone [40]. Because
only the DN thymocyte population expresses both
IL-7R and Kit in the thymus, the number of donor-
derived DNs was most profoundly affected by the
combined IL-7 and SCF MSC treatment in our data
as well (Figure 3B). Evidence supporting redundant
roles for IL-7R and Kit was provided in a recent study
where the interaction of IL-7R and Kit after Kit stim-
ulation resulted in amplification signals in the absence
of IL-7 [32].
The finding of increased donor-derived CLPs and
enhanced donor T cell development in SCF/IL-7
MSC recipients suggests that stimulation of the
IL-7R– and Kit-expressing BM-derived CLPs and
DN thymocytes enhances donor lymphocyte
Figure 7. Cotransplantation of IL-7 and SCF MSCs results in increased
anti-SRBC titer after immunization. Anti-SRBC agglutinating titers were
measured 2 weeks after the primary immunization (at day 44) and the
secondary immunization (at day 51) post-BMT. An asterisk indicates sig-
nificant differences between groups of animals that underwent trans-
plantation with the transduced MSCs (*P #.03; **P #.03; ***P #.04).
Each value represents the mean of 2 or 3 independent experiments
each with a total of 3-5 animals per group. Consistent results were ob-
tained in repeated experiments throughout. The vertical bold lines
branching off from the top of the horizontal lines represent statistically
significant P values when the 0.3  106 IL-71 0.3  106 SCF, 0.1  106
IL-71 0.3  106 SCF, and 0.3  106 IL-71 0.1  106 SCF groups were
individually compared with all other groups of animals.
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in the biology of CLP are not clear, our laboratory has
demonstrated that analyses of mice doubly mutated in
the gc subunit of IL-7R and Kit, in IL-7 and Kit, or in
IL-7R and Kit have decreased frequency and numbers
of CLPs, indicating that the regulation of the prolifer-
ation and survival of CLPs is dependent on IL-7 and
SCF signaling [49]. Moreover, Fahlman et al. [50] re-
ported that IL-7 and SCF synergize to promote the
proliferation of freshly isolated Lin-Sca11 murine
BM progenitor cells. A strategy that promotes the ex-
pansion of CLPs to restore immunity after BMT
might have important therapeutic applications. Arber
et al. [47] demonstrated that transplantation of CLPs
along with purified HSCs significantly enhanced early
lymphoid reconstitution and improved the survival
rate after an experimental challenge with murine cyto-
megalovirus compared with HSCT alone. Given the
very low frequency of CLPs in the BM, therapeutic
application of CLPs for transplantation likely would
require ex vivo expansion to be clinically relevant.
The therapeutic use of IL-7 and SCF to promote
proliferation of transplanted CLPs would accelerate
restoration of immunity without the need to transplant
high numbers of CLPs. Given that multipotent
progenitors (MMPs; Lin2Sca-11IL-7Ra2Kithi) and
more differentiated lymphoid-primed multipotent pro-
genitors (LMMPs; Lin2Sca-11IL-7Ra2Kithi) residing
in the BM compartment give rise to CLPs, it would
be interesting to analyze the effects of IL-7 and SCF
on both MMP and LMMP populations and their rela-
tions to overall immune reconstitution [45,51].Our IL-7/SCF gene therapy BMT model offers
several advantages for correction of immune deficiency.
We have previously shown that thymic microenviron-
mental defects are related to radiation damage to the
TECs and also to decreased intrathymic IL-7 transcript
levels [5,8]. As a result, the ability of the irradiated
thymus to support donor-derived T lymphocyte devel-
opment is severely impaired. With the aim of restoring
thymopoietic capacity after BMT, several groups have
demonstrated that s.c. injection of rhIL-7 into BMT
recipient animals results in normalization of thymopoi-
esis and immune reconstitution. Although s.c. injection
of hematopoietic cytokines can enhance immune recon-
stitution in murine BMT recipients, the engineering of
BM-derived MSCs to produce IL-7 or SCF might
provide several advantages over injection treatment
[34,35,37]. Administration of cytokines has been
associated with toxicity due to the high levels of short-
lived agents needed to achieve therapeutic effects. On
the other hand, the continuous production of IL-7 or
SCF from the transducedMSCsmight bemore physio-
logically effective and less toxic.The efficacy of cytokine
secretion by the transduced MSCs likely was increased
by higher local concentrations after their engraftment
in lymphohematopoietic organs (Figure 2A). Further-
more, studies have demonstrated that cotransplantation
of MSCs and HSCs enhances hematopoietic engraft-
ment, suggesting the ability of MSCs to promote
immune reconstitution [52-55]. The mechanisms
behind the enhanced hematopoietic engraftment by
MSC transplantation remain unclear, however. It is
possible that the release of various factors by the
BM-derived MSCs, including hematopoietic cytokines
and chemokines, combined with IL-7 and SCF in the
circulation further enhanced either engraftment or
expansion of donor-derived T lymphocytes in our con-
generic murine recipients. Although in the present
study, circulating levels of rhIL-7 and mSCF were
significantly higher in the engrafted mice compared
with control animals with no deleterious side effects,
a strategy to permit regulation of MSC expression (eg,
via an inducible vector or introduction of a suicide
gene in the vector to permit ablation) might be useful
for clinical studies as ameans to abet potential toxicities.
Finally, recent reports demonstrating that IL-7 can
cause expansion of mature T cells and that IL-7 treat-
ment after experimental allogeneic BMT increases the
frequency of GVHD suggest that IL-7 treatment after
BMT to enhance immune reconstitution in the alloge-
neic setting may have adverse effects [56]. We previ-
ously demonstrated that treatment of allogeneic BMT
recipients with anti–IL-7Ra antibody prevented
GVHD by blocking IL-7 signaling in donor mature
T cells, further suggesting the potential danger of using
IL-7 in an allogeneic setting [9]. The amount of IL-7
needed to develop GVHD is unknown, however.
Shinha et al. [10] reported that exacerbation of
Biol Blood Marrow Transplant 17:48-60, 2011 59Combined IL-7 and SCF Treatment in Murine BMTGVHD is directly related to the amount of IL-7 in-
jected into allogeneic BMT murine recipients. Our
current finding of greater enhancement of donor-
derived immune reconstitution in the recipients of com-
bined IL-7 and SCFMSCs compared with recipients of
IL-7MSCs alone provide a potential newmodel for en-
gineering of the immune system.ACKNOWLEDGMENTS
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